Skip to content

PHARNEXT: Pharnext proclaims the profitable switch of producing and the rise of its manufacturing capability of PXT3003 in the USA – 01/26/2023 at 08:30

PARIS, France, January 26, 2023 at 8:30 a.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA)

(the “Firm”), a late-stage biopharmaceutical firm creating novel therapies for neurodegenerative ailments with no passable therapeutic answer, proclaims immediately that it has efficiently transferred the manufacturing of PXT3003 from the Unither plant in Colomiers, France to the Unither’s American web site situated in Rochester (New York State) and elevated its manufacturing capability of PXT3003 in the USA. Pharnext is now capable of manufacture batches of three,500 liters of oral answer of PXT3003, a quantity probably appropriate with a industrial distribution chain of PXT3003.

If the outcomes of the pivotal Part III medical research of PXT3003 in Charcot-Marie-Tooth illness kind 1A (CMT1A), the PREMIER trial, are constructive on the 4


quarter of 2023 and that these permit acquiring a advertising and marketing authorization (AMM) in Europe and the USA, PXT3003 can be marketed within the type of a single-dose sachet of oral answer of 5 mL to be saved in chain chilly. Single-dose sachets are designed to ship a exact quantity of treatment in a secure method. The selection of this pharmaceutical type was guided by the need to supply a extra sensible and versatile answer to make use of for sufferers with CMT1A and consequently permit higher compliance with remedy.

The manufacturing of single-dose sachets of PXT3003 meant for the PREMIER trial is at present maintained on the Unither Colomiers manufacturing web site in France. The Unither Rochester web site can be reserved for industrial manufacturing. Pharnext is continuous to develop the manufacturing of single-dose oral answer sachets of PXT3003 within the Unither Rochester plant and can talk on this new stage when it’s accomplished.

Raj Thota, Director of Manufacturing and CMC, stated:

“I’m delighted that the switch of producing

and improve in manufacturing capability

of PXT3003 between Unither’s French and American websites passed off efficiently. It is a crucial step in getting ready for the potential commercialization of PXT3003, if our most superior product obtains advertising and marketing authorization in CMT1A, a illness for which there isn’t a particular therapeutic answer in the mean time. »

About Pharnext

Pharnext is a late-stage biopharmaceutical firm creating novel therapies for neurodegenerative ailments that at present don’t have any passable therapeutic answer. Pharnext has two merchandise in medical growth. PXT3003 has accomplished a global Part III trial with first constructive leads to Charcot-Marie-Tooth illness kind 1A (CMT1A) and has orphan drug standing in Europe and the USA. A pivotal worldwide Part III medical research of PXT3003 in CMT1A, the PREMIER trial, is at present underway. PXT864 has obtained encouraging Part II leads to Alzheimer’s illness and its growth will likely be pursued in partnerships. Pharnext’s two most superior drug candidates had been found with the Pleotherapy™ R&D strategy. Pharnext attracts traders’ consideration to the danger elements, notably the monetary ones detailed in its monetary reviews. Extra data on

Pharnext is listed on the Euronext Development market in Paris (ISIN code: FR001400BV89).


Press Relations (Worldwide)

Consilium Strategic Communications

Mary Jane Elliott

Sukaina Virji

Alexandra Harrison

Monetary Press Relations

NEWS finance & communication

Deborah Schwarz

+33 (0)1 53 67 36 35

Investor Relations

NEWS finance & communication

Jerome Fabreguettes Leib

+33 (0)1 53 67 36 78

This publish has the “🔒 Actusnews SECURITY MASTER” service.



– To test this key:

Regulated data:

Inside data:

– Different press releases

Full and authentic press launch in PDF format:

© Copyright Actusnews Wire

Obtain the corporate’s subsequent press releases freed from cost by e mail by subscribing to


Leave a Reply

Your email address will not be published. Required fields are marked *